Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy

1 Feb 2017

Abstract excerpt

Targeting CD47 is in the spotlight of cancer immunotherapy. Blocking CD47 triggers the recognition and elimination of cancer cells by the innate immunity. There are three CD47 antagonists in phase I clinical trials, but their potential efficacies are highly controversial. We raise our concern that NOD-based xenograft hosts tend to overestimate, while syngeneic mouse models could substantially underestimate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Erythrocyte Function and Pathophysiology
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28275508
DOI: 10.21037/jtd.2017.02.30

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CD47: the achievements and concerns of current studies on cancer immunotherapyPMID 28275508Read ↗

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα AxisSemantic proximity Read ↗

Blockade of CD47 or SIRPα: a new cancer immunotherapySemantic proximity Read ↗

Recent Advances of Tumor Therapy Based on the CD47-SIRPα AxisSemantic proximity Read ↗

Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.Semantic proximity Read ↗

Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsSemantic proximity Read ↗

A Novel Anti-CD47 Nanobody Tetramer for Cancer TherapySemantic proximity Read ↗

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell MetastasisSemantic proximity Read ↗

Role of CD47 in tumor immunity: a potential target for combination therapySemantic proximity Read ↗

Breaking the ‘Don’t Eat Me’ Signal: In Silico Design of CD47 Directed Peptides for Cancer ImmunotherapySemantic proximity Read ↗

A multidimensional pan-cancer analysis of CD47 and its role in promoting malignant phenotype in pancreatic adenocarcinoma.Semantic proximity Read ↗

CD47 expression is critical for CAR T-cell survival in vivoSemantic proximity Read ↗

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.